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In a case–control study using a large UK primary care database, we found that non-steroidal anti-inflammatory drugs had no
protective effect against biliary carcinomas (cholangiocarcinoma and gall bladder cancer). Increased risks were observed for cigarette
smoking, diabetes, gallstone disease and obesity.
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Cholangiocarcinoma has a 5-year survival rate of only 20%
(Nathan et al, 2007). It is becoming more common in both the
UK and the USA. At the same time, the incidence of the
other cancer of the biliary epithelium (gall bladder cancer) has
declined (West et al, 2006). Risk factors for cholangiocarcinoma
include primary sclerosing cholangitis, gallstone disease (Ekbom
et al, 1993), HCV infection (Donato et al, 2001), diabetes and
obesity (Welzel et al, 2007). Gall bladder cancer has been
previously linked with gallstone disease (Serra et al, 1996)
and cigarette smoking (Yagyu et al, 2008). It has been suggested
that cyclooxygenase (COX) inhibition might have potential for
chemoprevention in cholangiocarcinoma as COX-2 expression
inhibits apoptosis in cholangiocarcinoma cells (Sirica et al, 2001).
We set out to examine the role of the above risk factors in a
large UK primary care-based population and, for the first
time, to assess whether non-steroidal anti-inflammatory drugs
(NSAIDs) protect against cholangiocarcinoma and gall bladder
cancer.
MATERIALS AND METHODS
The General Practice Research Database (GPRD) is a large
longitudinal primary care database containing the primary care
records of more than 8 million patients in the UK. The GPRD data
are audited to ensure that at least 95% of medical events and
prescriptions are satisfactorily recorded (Walley and Mantgani,
1997) and have been shown to provide results consistent with
other UK data sources (Hollowell, 1997).
We identified people in the GPRD between 1987 and March 2002
with a recorded diagnosis of cholangiocarcinoma or gall bladder
cancer using the Oxford Medical Information System and Read
Clinical Classification codes. Cases were categorised into three
groups: definite cholangiocarcinoma, definite gall bladder cancer,
and a group containing patients who had both types of cancer
coded or had codes that could not distinguish between them. The
index date for cases was taken as the date of first diagnosis of
biliary cancer. A total of 10 controls were matched to each case by
GP practice, sex and age (within 5 years of the case). We excluded
controls with less than 1 year of exposure data prior to case
diagnosis.
Risk factors of interest were history of liver disease (including
cirrhosis, hepatitis, primary sclerosing cholangitis, gallstone-
related disease) or diabetes, prior NSAID use and lifestyle
factors (smoking, alcohol and body mass index (BMI)). Any
diagnoses occurring later than 6 months prior to the index date
were excluded. Non-steroidal anti-inflammatory drug use was
defined as any prescription of a drug listed under section 10.1.1 of
the British National Formulary (No. 54). Analyses were repeated
with exposure being classified by use at different time points
preceding case diagnosis. We also repeated the analysis by
excluding prescriptions for aspirin to ascertain the effect of non-
aspirin NSAID use. Smoking status and alcohol intake were
recorded at 1 year prior to the date of case diagnosis (or closest
record prior to this). For alcohol intake, ‘problem drinkers’ were
defined as those with a GPRD code indicating alcohol misuse at
any time prior to diagnosis. Body mass index was calculated as
weight in kg/height in m
2. A separate category was created for the
smoking, alcohol or BMI variables related to participants who had
missing data.
Data were analysed using conditional logistic regression,
with results presented as odds ratios (ORs) with 95% confidence
intervals (CIs). Results were adjusted a priori for smoking,
alcohol and BMI, with NSAID use also adjusted for gallstone
disease diagnosis. Analyses were performed using the entire
case group, and then separately for cholangiocarcinoma and
gall bladder cancer cases. Stata version 10.0 was used for all
analyses.
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Selection of cases and controls
We identified 611 cases, 372 cholangiocarcinomas, 184 gall bladder
cancers and 55 unspecified biliary cancers. In total, 5760 controls
were matched to the cases. The median duration of exposure data
available prior to the date of case diagnosis was 4.8 years for cases
(range 1.0–12.4 years) and 4.4 years for controls (range 1.0–12.5
years). The percentage of male cases was greater for cholangio-
carcinoma (48.4%) than for gall bladder cancer (26.1%), whilst the
mean age at diagnosis was similar for the two cancer types (71.3
(s.d. 12.0) years vs 72.0 (s.d. 11.1) years).
Chronic liver disease and diabetes
Only small numbers of viral hepatitis (n¼3), cirrhosis (n¼2) and
PSC (n¼1) occurred among cholangiocarcinoma cases and none
occurred among cases of gall bladder cancer. Only gallstone
disease occurred with sufficient frequency to allow appropriate
comparison of cases and controls, which was associated with a
more than three-fold risk of gall bladder cancer and almost two-
fold risk of cholangiocarcinoma (Table 1). The prevalence of
diabetes was 8.5% in cases, which was significantly higher than the
5.9% in controls (OR¼1.39; 95% CI, 1.01–1.90).
NSAID use
A previous NSAID prescription was received by approximately
50% of both cases and controls, with no significant difference
between the groups overall (OR¼0.95; 95% CI, 0.80–1.13). In the
interval 24–36 months preceding case diagnosis, there was
significantly more NSAID use among cholangiocarcinoma cases
(OR¼1.34); however, in all other time intervals and among gall
bladder cases ORs were close to 1 (Table 1). When we repeated this
analysis for non-aspirin NSAIDs the findings did not change
materially, with a slightly increased risk for cholangiocarcinoma in
the 24–36-month period preceding diagnosis (OR¼1.32; 95% CI,
1.00–1.75) and ORs closer to 1 in all other instances (data not
shown).
BMI, cigarette smoking and alcohol
We found that obese patients (BMIX30kg/m
2) had 1.5 times the
risk of both cholangiocarcinoma and gall bladder cancer when
compared with those with BMI o25kg/m
2 (Table 1). An increased
risk was also observed among cigarette smokers, which was
significant both among the entire series of cases (OR¼1.48) and
for the individual cancer types. We found neither current alcohol
use nor problem alcohol drinking to be associated with either
cancer (Table 1).
DISCUSSION
This is the first epidemiological study to examine the potential for
chemoprevention of cholangiocarcinoma by the use of NSAIDs.
Cyclooxygenase-2 is overexpressed in cholangiocarcinoma cells
(Wu et al, 2002), is involved in apoptosis in these cells (Sirica et al,
2001), and its inhibition by Celecoxib has been shown in vivo to
Table 1 Risk factors for cholangiocarcinoma and gall bladder cancer: analysis with adjustment for cigarette smoking, alcohol consumption and BMI
a
Controls Cases
(n¼5760) All (n¼611) Cholangiocarcinoma (n¼372) Gall bladder cancer (n¼184)
N (%) N (%) OR (95% CI) N (%) OR (95% CI) N (%) OR (95% CI)
History of diabetes or liver disease 46 months prior to case diagnosis
Diabetes mellitus 342 (5.9) 52 (8.5) 1.39 (1.01–1.90) 35 (9.4) 1.48 (1.00–2.17) 16 (8.7) 1.43 (0.81–2.52)
Cirrhosis 6 (0.1) 2 (0.3) Not estimable 2 (0.5) Not estimable 0 (0.0) Not estimable
Viral hepatitis (excluding type A) 23 (0.4) 3 (0.5) Not estimable 3 (0.8) Not estimable 0 (0.0) Not estimable
Primary sclerosing cholangitis 1 (o0.1) 1 (0.2) Not estimable 1 (0.3) Not estimable 0 (0.0) Not estimable
Gallstone disease 268 (4.7) 66 (10.8) 2.34 (1.75–3.14) 33 (8.9) 1.78 (1.19–2.67) 27 (14.7) 3.57 (2.19–5.81)
Any NSAID prescription (stratified by interval preceding case diagnosis)
b
46 months 3004 (52.2) 321 (52.5) 0.95 (0.80–1.13) 209 (56.2) 1.00 (0.80–1.26) 88 (47.8) 0.87 (0.63–1.21)
6–12 months 1419 (24.6) 159 (26.0) 1.04 (0.86–1.27) 108 (29.0) 1.12 (0.88–1.42) 40 (21.7) 0.90 (0.61–1.33)
12–24 months 1467 (30.9) 167 (32.4) 1.01 (0.82–1.24) 109 (34.3) 1.05 (0.81–1.35) 46 (29.1) 0.90 (0.61–1.32)
24–36 months 1188 (29.9) 152 (34.6) 1.19 (0.96–1.48) 108 (38.3) 1.34 (1.03–1.74) 39 (31.0) 1.03 (0.67–1.58)
36–60 months 909 (35.3) 114 (39.2) 1.17 (0.90–1.53) 77 (39.5) 1.21 (0.88–1.68) 32 (40.0) 1.09 (0.65–1.84)
Current cigarette smoker
c 759 (20.9) 108 (26.8) 1.48 (1.16–1.89) 70 (27.5) 1.38 (1.01–1.87) 28 (24.8) 1.61 (1.00–2.62)
BMI index (kg/m
2)
c
o25 1380 (45.6) 132 (39.1) 1.00 88 (39.1) 1.00 36 (41.9) 1.00
25–o30 1156 (38.4) 137 (40.5) 1.28 (0.99–1.66) 93 (41.3) 1.33 (0.97–1.82) 31 (36.1) 1.03 (0.62–1.72)
X30 471 (15.7) 69 (20.4) 1.58 (1.15–2.16) 44 (19.6) 1.52 (1.03–2.24) 19 (22.1) 1.51 (0.83–2.75)
Alcohol consumption
c
Alcohol abstainer 678 (23.1) 81 (24.4) 1.00 50 (23.5) 1.00 26 (28.6) 1.00
Alcohol user 2237 (76.2) 249 (75.0) 0.93 (0.70–1.23) 162 (76.1) 0.90 (0.63–1.29) 65 (71.4) 0.99 (0.59–1.64)
Problem drinker 19 (0.7) 2 (0.6) Not estimable 1 (0.3) Not estimable 0 (0.0) Not estimable
BMI¼body mass index; CI¼confidence interval; NSAID¼non-steroidal anti-inflammatory drug; OR¼odds ratio.
aSmoking was categorised as current smoking, non-smoking,
missing; alcohol consumption as non-drinking, current drinking, problem drinking, missing; and BMI into four categories, including missing.
bNSAID use is also adjusted for history
of gallstone disease in the previous 6 months.
cSmoking data were unavailable for 34% of cases and 39% of controls, alcohol data for 46% of cases and 49% of controls, and BMI
for 45% of cases and 48% of controls. Percentages and ORs for these variables were based on cases and controls with available data. All ORs were obtained using conditional
logistic regression for matched cases and controls. ORs were not presented when either the number of exposed cases or the number of exposed controls was o5o w i n gt o
unreliability of the accompanying 95% CI in these instances.
Antecedents of biliary cancer
MJ Grainge et al
179
British Journal of Cancer (2009) 100(1), 178–180 & 2009 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
yinduce apoptosis in them (Wu et al, 2003). Despite this, no benefit
from NSAIDS was found among our study group. Protective effects
of NSAIDs on other GI tumors have been shown earlier using the
same data set and methods similar to those we have used
(Langman et al, 2000). A post hoc power calculation showed that
our study had 90% power to detect a 25% reduction in risk with
previous NSAID use; hence, our negative result was not because of
lack of statistical power. One weakness of our study with respect to
NSAIDs is that owing to their limited use in the UK there were not
enough data to permit us to examine COX-2 inhibitors separately
from other NSAIDs. This does not invalidate our results for
NSAIDs, but leaves open the possibility that a more selective COX-
2 inhibition may have a chemoprotective effect.
Our study confirms a number of earlier-described associations
with other risk factors. We have been able to not only confirm the
long-recognised association of gallstone disease (OR 2.34), but also
reproduce significant associations with smoking (OR 1.48) and
obesity (OR 1.58 for comparison of BMIo25 and BMIX30). We
also found an association with diabetes of a magnitude similar to
that reported in a recent publication from the SEER study (Welzel
et al, 2007). We did not, however, in contrast to previous research
(Shaib et al, 2007), find an association with alcohol intake.
Exposure to PSC, cirrhosis or viral hepatitis was very rare within
our study, hence greatly limiting our power to examine these
factors.
Our results are not susceptible to selection bias as our study is
population-based, using all available cases and appropriately
selected controls from the same population. Nor, given the
prospective recording of exposure data, is it prone to ascertain-
ment bias beyond that because of the increased medical attention
to which cases will inevitably be exposed in the run-up to and after
their diagnosis. We have attempted to minimise this bias that
might affect some of our risk estimates (such as those with
diabetes and PSC) by excluding exposures later than 6 months
before diagnosis from our analysis. One limitation of our study is
that unlike in earlier studies, we are unable to say whether
cholangiocarcinoma is intra- or extra-hepatic, nor to access
histological or radiological records to validate the diagnosis. We
think it unlikely that UK general practitioners would make a
diagnosis of cholangiocarcinoma, and so we believe that the
diagnoses are as secure as those in UK secondary care. Much of the
quoted literature, however, refers specifically to intra-hepatic
cholangiocarcinoma; therefore, if the risk factors for carcinogen-
esis vary by site within the biliary epithelium, this might explain
why viral hepatitis and cirrhosis (if they affect intrahepatic more
than extrahepatic ducts) occur less frequently in our study when
compared with others (Donato et al, 2001).
In summary, this large population-based case–control study of
biliary carcinomas has shown no protective effect from NSAIDs. It
has, though, confirmed the increased risk of diabetes mellitus and
gallstone disease, which earlier studies have found for cholangio-
carcinoma, and has provided population-based estimates of the
magnitudes of these associations. It has also highlighted the role of
PSC, viral hepatitis and cirrhosis, but shows that although
cholangiocarcinoma risk may be high in people with these risk
factors, they explain little of the disease occurrence.
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